title: Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients.
abstract: Breast cancer during pregnancy (BCP), although rare, is becoming more common and treatment should be as similar as possible to that for nonpregnant young patients with breast cancer. A group of specialists convened to review current guidelines and provide guidance on how recent advances in breast cancer diagnosis and treatment can be adapted for pregnant patients. The majority of patients with BCP will be considered for treatment during the pregnancy. Premature delivery should be avoided whenever possible. Most treatments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-dense treatment can be safely given during pregnancy, after careful risk/benefit assessment for mother and child. Chemotherapy is contraindicated during the first trimester because of a higher risk of fetal malformations but is feasible in the second and third trimesters. Other treatments such as radiation therapy or anti-human epidermal growth receptor 2 treatment are in general not indicated during pregnancy but might be considered in some instances. Patient data should be collected in a systematic way whenever possible.
authors.affiliation: German Breast Group, Neu-Isenburg, Germany2Sana Klinimum, Offenbach, Germany.
authors.forename: Sibylle
authors.initials: S
authors.lastname: Loibl
authors.affiliation: University Hospital Jena, Jena, Germany.
authors.forename: André
authors.initials: A
authors.lastname: Schmidt
authors.affiliation: European Institute of Oncology, Milano, Italy.
authors.forename: Oreste
authors.initials: O
authors.lastname: Gentilini
authors.affiliation: Chaim Sheba Medical Center, Ramat Gan, Israel.
authors.forename: Bella
authors.initials: B
authors.lastname: Kaufman
authors.affiliation: University of Aachen, Aachen, Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: Kuhl
authors.affiliation: Charite Berlin, Berlin, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Denkert
authors.affiliation: German Breast Group, Neu-Isenburg, Germany.
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
authors.affiliation: Blochin Cancer Research Center, Moscow, Russia.
authors.forename: Anastasia
authors.initials: A
authors.lastname: Parokonnaya
authors.affiliation: Department of Oncology, Oslo University Hospital, Oslo, Norway.
authors.forename: Hanne
authors.initials: H
authors.lastname: Stensheim
authors.affiliation: University Hospital Halle (Saale), Halle (Saale), Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Thomssen
authors.affiliation: University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: Kristel
authors.initials: K
authors.lastname: van Calsteren
authors.affiliation: Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Philip
authors.initials: P
authors.lastname: Poortmans
authors.affiliation: Trousseau Hospital, Paris, France.
authors.forename: Paul
authors.initials: P
authors.lastname: Berveiller
authors.affiliation: University Hospital Jena, Jena, Germany.
authors.forename: Udo R
authors.initials: UR
authors.lastname: Markert
authors.affiliation: Leuven Cancer Institute, Leuven, Belgium.
authors.forename: Frederic
authors.initials: F
authors.lastname: Amant
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome